FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1058-1059 September 4, 2008 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Poole, J. E. Related Article by Mark, D. B. PubMed Citation

Randomized trials have established that the prophylactic use of implantable cardioverter–defibrillators (ICDs) prolongs survival in patients with left ventricular dysfunction that is due to myocardial infarction¹ or associated with heart failure from any cause.² One of the pivotal trials, the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (ClinicalTrials.gov number, NCT00000609 [ClinicalTrials.gov] ), compared ICD therapy or amiodarone with placebo in 2521 patients with symptomatic heart failure due to ischemic or nonischemic left ventricular dysfunction.² That trial showed that among patients who had an ICD as compared with those who received a placebo, there was an absolute reduction in mortality of . . . [Full Text of this Article]

Source Information

From the Division of Cardiology, Hamilton Health Sciences Centre, McMaster University, Hamilton, ON, Canada.

This article has been cited by other articles:

• (2008). QOL and Mortality Among Heart Failure Patients with Implantable Cardioverter-Defibrillators. JWatch General 2008: 4-4 [Full Text]  
• (2008). Beware of Implantable Cardioverter-Defibrillator Shocks!. Journal Watch Cardiology 2008: 2-2 [Full Text]